Literature DB >> 12942453

An evaluation of long-term outcomes after liver transplantation for cryptogenic cirrhosis.

Michael A Heneghan1, Teresa Zolfino, Paolo Muiesan, Bernard C Portmann, Mohammed Rela, Nigel D Heaton, John G O'grady.   

Abstract

Patients with cryptogenic cirrhosis (CC) comprise a significant proportion of liver transplant recipients. Poor outcome after transplantation has been reported by some centers, with fibrosis occurring in a significant proportion of patients. Outcome of 46 patients with CC who underwent transplantation between 1989 and 1999 at King's College Hospital London were compared with time-matched recipients who underwent transplantation for hepatitis C virus (HCV) cirrhosis (n = 58) and patients with alcohol-related cirrhosis (AC, n = 53) during the same time period. Mean follow-up was 46 +/- 37 months for CC patients, 41 +/- 31 months for AC patients, and 49 +/- 31 months for HCV patients. No protocol liver biopsy specimens were obtained, and biopsies were performed only for investigation of biochemical abnormalities. Acute cellular rejection occurred in 30% of CC, 26% of AC, and 37% of HCV patients (P = NS). Overall patient and graft survival at 1 year was 85% and 80% for CC patients, 87% and 81% for AC patients, and 91% and 82% for patients with HCV (P = NS). Five-year patient and graft survival was 81% and 77% for CC patients, 60% and 48% for AC patients, and 79% and 57% for HCV patients (Log rank; P =.369). Twenty-two percent of CC patients had inflammation on last evaluable liver biopsy, compared with 25% of patients who underwent transplantation for AC and 68% of patients who underwent transplantation for HCV. No patient who underwent transplantation for CC had histologic evidence of cirrhosis on last evaluable biopsy, compared with 2% of patients who underwent transplantation for AC and 16% of patients who underwent transplantation for HCV (Chi-squared = 13.053, P =.0015). These results suggest that CC is a favorable indication for OLT and that although a proportion of patients develop inflammation in the liver allograft, this does not result in significant graft dysfunction or loss.

Entities:  

Mesh:

Year:  2003        PMID: 12942453     DOI: 10.1053/jlts.2003.50165

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

Review 1.  Cryptogenic cirrhosis: what are we missing?

Authors:  Stephen Caldwell
Journal:  Curr Gastroenterol Rep       Date:  2010-02

Review 2.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

Review 3.  Cryptogenic chronic hepatitis and its changing guise in adults.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-06-07       Impact factor: 3.199

4.  The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes.

Authors:  A Sidney Barritt; Evan S Dellon; Tomasz Kozlowski; David A Gerber; Paul H Hayashi
Journal:  J Clin Gastroenterol       Date:  2011-04       Impact factor: 3.062

5.  Nonalcoholic fatty liver disease following liver transplantation.

Authors:  Sanjaya Kumar Satapathy; Satheesh Nair; Jason M Vanatta
Journal:  Hepatol Int       Date:  2013-04-26       Impact factor: 6.047

6.  Inhibition of mouse hepatocyte apoptosis via anti-Fas ribozyme.

Authors:  Min Zhang; Wei He; Fang Liu; Ping Zou; Juan Xiao; Zhao-Dong Zhong; Zhong-Bo Hu
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

Review 7.  Long-term liver allograft fibrosis: A review with emphasis on idiopathic post-transplant hepatitis and chronic antibody mediated rejection.

Authors:  Mukul Vij; Ashwin Rammohan; Mohamed Rela
Journal:  World J Hepatol       Date:  2022-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.